ViiV Healthcare announced today that the U.S. Food and Drug Administration (FDA) has approved its all-in-1 antiretroviral fixed-dose combination pill containing the HIV integrase inhibitor dolutegravir (Tivicay) plus abacavir and lamivudine (the drugs in Epzicom or Kivexa). The new coformulation -- with the brand name Triumeq -- is the first single-tablet regimen that does not contain tenofovir and emtricitabine, making it an option for people with impaired kidney function. HLA-B*5701 genetic screening should be done prior to starting Triumeq to test for abacavir hypersensitivity.
HIVandHepatitis.com coverage of the 20th International AIDS Conference (AIDS 2014), July 20-25, in Melbourne, Australia.
Conference highlights include biomedical HIV prevention (PrEP and treatment-as-prevention), HIV cure research, interferon-free therapy for hepatitis C and HIV/HCV coinfection, access to treatment, and fighting stigma and criminalization of key affected populations.
Cal Cohen of the Community Research Initiative of New England sat down with HIVandHepstitis.com to offer his summary of some of the highlights of HIV treatment and prevention research presented at the 20th International AIDS Conference last month in Melbourne, Australia.